BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 28194662)

  • 1. MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression.
    Christenson JL; Butterfield KT; Spoelstra NS; Norris JD; Josan JS; Pollock JA; McDonnell DP; Katzenellenbogen BS; Katzenellenbogen JA; Richer JK
    Horm Cancer; 2017 Apr; 8(2):69-77. PubMed ID: 28194662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Androgen Receptor Promotes Cellular Proliferation by Suppression of G-Protein Coupled Estrogen Receptor Signaling in Triple-Negative Breast Cancer.
    Shen Y; Yang F; Zhang W; Song W; Liu Y; Guan X
    Cell Physiol Biochem; 2017; 43(5):2047-2061. PubMed ID: 29059676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.
    Thakkar A; Wang B; Picon-Ruiz M; Buchwald P; Ince TA
    Breast Cancer Res Treat; 2016 May; 157(1):77-90. PubMed ID: 27120467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion.
    Williams TM; Medina F; Badano I; Hazan RB; Hutchinson J; Muller WJ; Chopra NG; Scherer PE; Pestell RG; Lisanti MP
    J Biol Chem; 2004 Dec; 279(49):51630-46. PubMed ID: 15355971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer.
    Wang X; Petrossian K; Huang MJ; Saeki K; Kanaya N; Chang G; Somlo G; Chen S
    J Steroid Biochem Mol Biol; 2021 Feb; 206():105791. PubMed ID: 33271252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
    Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
    Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiproliferative Effect of Androgen Receptor Inhibition in Mesenchymal Stem-Like Triple-Negative Breast Cancer.
    Zhu A; Li Y; Song W; Xu Y; Yang F; Zhang W; Yin Y; Guan X
    Cell Physiol Biochem; 2016; 38(3):1003-14. PubMed ID: 26938985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERβ1 inhibits metastasis of androgen receptor-positive triple-negative breast cancer by suppressing ZEB1.
    Song W; Tang L; Xu Y; Sun Q; Yang F; Guan X
    J Exp Clin Cancer Res; 2017 Jun; 36(1):75. PubMed ID: 28583190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo.
    Barton VN; D'Amato NC; Gordon MA; Lind HT; Spoelstra NS; Babbs BL; Heinz RE; Elias A; Jedlicka P; Jacobsen BM; Richer JK
    Mol Cancer Ther; 2015 Mar; 14(3):769-78. PubMed ID: 25713333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of two androgen receptor assays using adenoviral transduction of MMTV-luc reporter and/or hAR for endocrine screening.
    Hartig PC; Bobseine KL; Britt BH; Cardon MC; Lambright CR; Wilson VS; Gray LE
    Toxicol Sci; 2002 Mar; 66(1):82-90. PubMed ID: 11861975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes.
    McNamara KM; Yoda T; Nurani AM; Shibahara Y; Miki Y; Wang L; Nakamura Y; Suzuki K; Yang Y; Abe E; Hirakawa H; Suzuki T; Nemoto N; Miyashita M; Tamaki K; Ishida T; Brown KA; Ohuchi N; Sasano H
    Breast Cancer Res Treat; 2014 Jun; 145(2):281-93. PubMed ID: 24715382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model.
    Otsuka Y; Oikawa T; Yoshino H; Hashimoto S; Handa H; Yamamoto H; Hashimoto A; Sabe H
    Cell Commun Signal; 2018 Jan; 16(1):1. PubMed ID: 29329590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mint3 in bone marrow-derived cells promotes lung metastasis in breast cancer model mice.
    Hara T; Murakami Y; Seiki M; Sakamoto T
    Biochem Biophys Res Commun; 2017 Aug; 490(3):688-692. PubMed ID: 28634075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling.
    Narayanan R; Ahn S; Cheney MD; Yepuru M; Miller DD; Steiner MS; Dalton JT
    PLoS One; 2014; 9(7):e103202. PubMed ID: 25072326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secreted indicators of androgen receptor activity in breast cancer pre-clinical models.
    Hanamura T; Christenson JL; O'Neill KI; Rosas E; Spoelstra NS; Williams MM; Richer JK
    Breast Cancer Res; 2021 Nov; 23(1):102. PubMed ID: 34736512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers of residual disease, disseminated tumor cells, and metastases in the MMTV-PyMT breast cancer model.
    Franci C; Zhou J; Jiang Z; Modrusan Z; Good Z; Jackson E; Kouros-Mehr H
    PLoS One; 2013; 8(3):e58183. PubMed ID: 23520493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced androgen receptor expression accelerates the onset of ERBB2 induced breast tumors in female mice.
    Hodgson MC; Vanostran G; Alghamdi S; Poppiti RJ; Agoulnik AI; Agoulnik IU
    PLoS One; 2013; 8(4):e60455. PubMed ID: 23593223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer.
    Schwab LP; Peacock DL; Majumdar D; Ingels JF; Jensen LC; Smith KD; Cushing RC; Seagroves TN
    Breast Cancer Res; 2012 Jan; 14(1):R6. PubMed ID: 22225988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SK4 channels modulate Ca
    Steudel FA; Mohr CJ; Stegen B; Nguyen HY; Barnert A; Steinle M; Beer-Hammer S; Koch P; Lo WY; Schroth W; Hoppe R; Brauch H; Ruth P; Huber SM; Lukowski R
    Mol Oncol; 2017 Sep; 11(9):1172-1188. PubMed ID: 28557306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells.
    Caiazza F; Murray A; Madden SF; Synnott NC; Ryan EJ; O'Donovan N; Crown J; Duffy MJ
    Endocr Relat Cancer; 2016 Apr; 23(4):323-34. PubMed ID: 26932782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.